Celgene Acquires Avila Therapeutics for $350,000,000

  • Feed Type
  • Date
  • Company Name
    Avila Therapeutics
  • Mailing Address
    45 Wiggins Avenue Bedford, MA 01730
  • Company Description
    Avila Therapeutics, Inc., is a venture-backed company focused on the discovery and development of novel small molecule therapeutics to address significant unmet clinical needs with an initial focus on cancer and viral diseases.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Under the terms of the merger agreement, Celgene will acquire Avila Therapeutics, Inc. for $350 million in cash, plus up to $195 million for milestones contingent upon the development and regulatory approval of AVL-292, as well as up to $380 million in potential milestone payments contingent upon the development and approval of candidates generated from the Avilomics platform.

Trending on Xconomy